Russian pharma market rises 25% in 1st-qtr amid fears of shortages
The value of the Russian pharmaceutical market amounted to 156.1 billion roubles (around $3 billion) in wholesale prices in the first quarter of 2015, which is 25% more than during the same period of 2014, according to a recent report of DSM Group, one of Russia’s leading analyst agencies in the field of pharmaceutics.
In volume terms, 1.1 billion drug packs were sold, which is by 3.2% more, compared to the same period of last year, reports The Pharma Letter’s local correspondent.
According to Sergei Shuljak, chief executive of DSM, the increase in sales was mainly the result of seasonal morbidity. In addition, many customers chose to buy drugs for future use, amid the fears of further price growth.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze